Business Context and Reporting Period
This Form 8-K Current Report was filed by IDEAYA Biosciences, Inc. on June 30, 2020, covering events occurring on June 26, 2020. The filing primarily addresses corporate governance changes, specifically the appointment of a new member to the Board of Directors.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the appointment of a director and associated compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors increased its size from six to seven members.
- New Appointment: Garret Hampton was appointed as a Class I independent director, effective June 26, 2020, with a term expiring at the 2023 annual meeting.
- Compensation Grant: Mr. Hampton received an option to purchase 22,000 shares of common stock. The exercise price equals the closing price on June 26, 2020. The option vests monthly over 36 months, contingent on continued service.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of specific risks or contingencies beyond the standard disclosure that there are no undisclosed arrangements regarding the director's appointment. Mr. Hampton has not been assigned to any board committees at this time.
Investor Verification Checklist
- Verify the closing stock price on June 26, 2020, to determine the exercise price of the 22,000 share option granted to Mr. Hampton.
- Review the Definitive Proxy Statement on Schedule 14A (filed April 27, 2020) for details on the standard non-employee director compensation program.
- Confirm the independence status of Mr. Hampton under Nasdaq listing standards as stated in the filing.
- Check for any subsequent committee assignments for Mr. Hampton, as none were named at the time of this filing.